Results 1 to 10 of about 143,709 (342)
Surface levels of CD20 determine anti-CD20 antibodies mediated cell death in vitro. [PDF]
PLoS ONE, 2014 The sensitivity of human Burkitt's lymphoma cells to rituximab (Rtx) and tositumomab (Tst) was assessed on cells expressing different levels of CD20 on surface.
Vijay Singh +5 more
doaj +4 more sources
A CCL5+CD20+CD8+ T cell subset drives pathogenic transformation of synoviocytes in rheumatoid arthritis via JAK-STAT signaling [PDF]
Cell & BioscienceBackground In rheumatoid arthritis (RA), fibroblast-like synoviocytes (FLS) acquire an aggressive phenotype promoting inflammation and joint damage. While FLS interactions with recruited T cells are established, drivers of FLS aggressiveness and the role
Haonan Jia +12 more
doaj +2 more sources
CD4 and CD20 as important immune markers in patients with pulmonary tuberculosis [PDF]
E3S Web of Conferences, 2023 Tuberculosis (TB) is a serious lung infection caused by the bacterium Mycobacterium tuberculosis (M. tuberculosis) is highly contagious, and can be spread through the air from an infected person to others.
Kamoona Firas Mohammad Hussein +1 more
doaj +1 more source
Non-Hodgkin lymphoma of cauda equina: A diagnostic conundrum: Case report
Advanced Biomedical Research, 2023 Primary central nervous system lymphoma (PCNSL) is uncommon with scarce cases having involvement of the spinal cord. Cauda equina is unique in its location and shows very rare involvement by diseases pathologies.
Pranati Misra +5 more
doaj +1 more source
CD20 and CD19 targeted vectors induce minimal activation of resting B lymphocytes [PDF]
, 2013 B lymphocytes are an important cell population of the immune system. However, until recently it was not possible to transduce resting B lymphocytes with retro- or lentiviral vectors, making them unsusceptible for genetic manipulations by these vectors ...
A Pezzutto +51 more
core +6 more sources
Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies [PDF]
mAbs, 2020 Current combination therapies elicit high response rates in B cell malignancies, often using CD20 antibodies as the backbone of therapy. However, many patients eventually relapse or develop progressive disease. Therefore, novel CD20 antibodies combining multiple effector mechanisms were generated.
Mitchell Evers +12 more
openaire +7 more sources
Important Diagnostic Clues for Diagnosing Splenic Marginal Zone Lymphoma in Absence of Splenic Histology [PDF]
Journal of Clinical and Diagnostic Research, 2017 Splenic Marginal Zone Lymphoma (SMZL) is a rare B-cell neoplasm comprising less than 2% of non-Hodgkin lymphomas. We hereby report a case of SMZL in a 66-year-old female who presented with fever and massive splenomegaly.
Anisha Mohanpuria +4 more
doaj +1 more source
Успехи молекулярной онкологии, 2021 Introduction. Non-small cell lung cancer is a common cancer with a poor prognosis. Modern researchers conduct many studies devoted to understanding the molecular mechanisms of its pathogenesis. Modern advances in immunotherapy have significantly improved
O. V. Kovaleva +5 more
doaj +1 more source
On the markers for schizophrenia
Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева, 2021 Summary. The study of various markers indicating an imbalance in both the neurotransmitter and immune systems observed in patients with schizophrenia is currently of great scientific and practical interest.
A. N. Erichev +4 more
doaj +1 more source
Monoclonal antibodies targeting CD20 [PDF]
mAbs, 2013 Letter to the Editor: We are commenting on the article by Klein et al. on the functional properties of several anti-CD20 monoclonal antibodies (mAbs) in the January/February 2013 issue of this journal.1 Rituximab, the first monoclonal antibody approved for cancer therapy, has truly revolutionized the treatment of a variety of CD20+ hematological ...
Chang, Chien-Hsing +2 more
openaire +2 more sources